Quick Facts

• Condition: Recurrent low-grade serous ovarian cancer (LGSOC) with a KRAS mutation
• Benefit: Provides a treatment specifically for this type of rare cancer

---

Conpac: Uses and Therapeutic Benefits

Conpac (avutometinib capsules, co-packaged with FAKZYNJA [defactinib]) is used for the management of adult patients diagnosed with recurrent low-grade serous ovarian cancer (LGSOC) that possesses a specific genetic alteration known as a KRAS mutation. This co-packaged therapy represents a treatment option for this disease population, which previously had limited therapeutic options.

The therapeutic benefit of using Conpac is the targeted treatment of this rare form of cancer. The combination therapy is intended to provide a more comprehensive blockade of the cellular signaling pathway that drives the growth and drug resistance of tumors dependent on the RAS/MAPK pathway. The goal of this treatment is to help manage the disease in patients who have received one or more prior lines of therapy, including platinum-based chemotherapy.

Regulatory References

1. FDA therapeutic overview

Official Eligibility Profile

The eligibility for Conpac (avutometinib/defactinib) is strictly defined by regulatory authorities based on patient population, disease state, and physiological status.

Approved Population Status

Category	Regulatory Statement
Eligible Age Group	Indicated only for adult patients (18 years of age and older). Safety and effectiveness have not been established in pediatric patients (children and adolescents).
Disease-Specific Eligibility	Restricted to patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. Individuals without this specific genetic biomarker or disease history are not eligible.
Absolute Contraindications	None are listed in the dedicated Contraindications section of the Prescribing Information.

Conditional and Restricted Use

Use is not studied and therefore not recommended in populations with severe renal impairment ( CrCl < 30 mL/min) or moderate or severe hepatic impairment. Furthermore, patients with a history of certain serious conditions, such as Rhabdomyolysis, are generally excluded from treatment.

Pregnancy and Lactation

Conpac is advised against during pregnancy due to the risk of fetal harm (Embryo-Fetal Toxicity). Females of reproductive potential must verify non-pregnant status and use effective contraception during and for 1 month after therapy. Likewise, breastfeeding is not recommended during treatment and for 2 weeks after the last dose.

Conpac Interactions with Other Medicines and Products

The official regulatory profile for Conpac (Avutometinib / Defactinib) documents several clinically significant interaction patterns, largely based on its metabolic clearance and absorption requirements. Defactinib is formally recognized as a substrate of the CYP3A4 enzyme. This pharmacokinetic classification dictates that the co-administration of strong or moderate CYP3A4 inhibitors is restricted because they can increase drug exposure, while the use of strong or moderate CYP3A4 inducers is similarly prohibited as they can decrease exposure. St. John's Wort and grapefruit/grapefruit juice are specifically documented to be avoided due to their role as modulators of this pathway.

A critical restriction exists regarding the drug's absorption, which is pH-dependent. Gastric acid reducing agents, including Proton Pump Inhibitors (PPIs) and H2-receptor antagonists, are prohibited as they severely reduce Defactinib plasma levels. Locally acting antacids require a specific timing separation rule: they must be administered two hours before or two hours after the Defactinib component. Separately, the labeling requires the avoidance of concomitant use with specific anticoagulants, such as Warfarin. Furthermore, the regulatory profile notes that Severe Hepatic Impairment is a population-specific consideration that may impact the overall management of interaction risks.

How Conpac Works

The mechanism of Dalteparin Sodium (Conpac) is defined by its highly specific engagement with the enzymatic pathways responsible for blood coagulation, resulting in an alteration of the coagulation potential.

---

Targeted Enzyme Potentiation via Antithrombin III

Dalteparin is not an anticoagulant itself; it functions by binding to the endogenous plasma protein Antithrombin III (ATIII) and causing a conformational change. This molecular interaction facilitates an acceleration of ATIII's inherent ability to neutralize specific activated clotting factors. This potentiation is the initial step that determines the drug's subsequent mechanistic effects.

---

Selective Inhibition of Factor Xa and Cascade Control

The principal consequence of ATIII potentiation is the accelerated neutralization of Factor Xa, a pivotal enzyme in the coagulation cascade. By preferentially inhibiting Factor Xa, the drug limits the production of Thrombin, which consequently reduces the conversion of Fibrinogen to the structural clot component, Fibrin. This selective modulation of the clotting cascade results in a reduced capacity for Fibrin polymerization.

How to Use Conpac: Official Administration Guidelines

Conpac is a co-packaged therapy consisting of Avutometinib capsules and Defactinib tablets, with administration governed by a precise, cyclic schedule.

---

Administration Scope

Instruction Domain	Official Guideline
Route of administration	Both Avutometinib and Defactinib are administered via the oral route.
Timing in relation to meals	Both Avutometinib capsules and Defactinib tablets must be taken with food.
Preparation requirements	The capsules and tablets must be swallowed whole; they must not be crushed, broken, or chewed.
Population-specific rules	No initial dose adjustment is required for adult patients with mild or moderate renal impairment or those with baseline mild hepatic impairment.
Missed-dose rules	If an Avutometinib dose is missed by more than 24 hours, it should be skipped. If a Defactinib dose is missed by more than 6 hours, that dose should be skipped.

---

Dosing Schedule and Frequency Pattern

Conpac is utilized in repeating 28-day cycles. The treatment phase spans 21 consecutive days, followed by a 7-day rest period where neither component is administered.

During the 21-day treatment phase, the standard regimen involves two distinct frequencies:

• Avutometinib is taken twice weekly (on Day 1 and Day 4 of the treatment cycle).
• Defactinib is taken twice daily (BID) for the entire 21-day treatment phase.

This protocol mandates the coordinated use of the two components under specific ingestion conditions to ensure consistent administration over the long-term cyclic plan.

Research Evidence / Overview of Studies for Conpac (Dalteparin Sodium)

Evidence for Preventing Blood Clots (VTE Prophylaxis)

Research examining Dalteparin Sodium in the context of preventing blood clots, known as venous thromboembolism (VTE), has primarily involved large, international Randomized Controlled Trials (RCTs) and subsequent systematic reviews. These studies were applied in populations with characteristics associated with VTE risk, such as adults recovering from major orthopedic or abdominal surgery, and acutely ill medical patients who were temporarily immobile. Research monitored the incidence of outcomes such as deep vein thrombosis (DVT) and pulmonary embolism (PE), and all-cause mortality, as study endpoints. Placebo-controlled trials described observed patterns in the incidence of VTE events between the groups receiving Dalteparin Sodium and the placebo groups. Some trials also examined comparisons against Unfractionated Heparin (UFH).

Evidence for Treating Blood Clots in Cancer

The use of Dalteparin Sodium in patients with active cancer who have experienced a symptomatic VTE event was evaluated in specific, large-scale randomized clinical trials. These studies primarily compared Dalteparin Sodium against standard treatments, such as Vitamin K Antagonists (VKAs), over an extended treatment duration, typically six months. The key outcomes research examined were the rate of recurrent VTE events (both DVT and PE) and the rate of major bleeding complications. Studies described patterns observed in the studies in the rates of VTE recurrence across the Dalteparin Sodium groups and the VKA groups.

Evidence in Special Populations (Pediatric Use)

Research on Dalteparin Sodium in the context of VTE in pediatric patients was evaluated in smaller, single-arm, non-randomized clinical trials. Evidence relies largely on a surrogate endpoint known as the anti-Factor Xa (anti-Xa) level, which is a physiological strain marker. Studies monitored how quickly patients in different age groups reached a pre-defined anti-Xa level, which is a measurement of the anti-Factor Xa level. This evidence provides context but research does not determine whether an individual will respond similarly, as the findings describe group patterns based on this specific biomarker.

What Research Gaps and Uncertainties Remain

Research on Dalteparin Sodium highlights areas where further study is needed. Comparative evidence against certain newer antithrombotic agents remains an area of ongoing research. For the pediatric population, the sample sizes were modest in the primary trials, and the reliance on a surrogate endpoint means that data regarding long-term clinical outcomes in children are not fully characterized. The evidence highlights what is known, and what is still uncertain, regarding long-term effects extending past the typical study follow-up periods.

Key Studies & References

1. Dalteparin and enoxaparin for unstable angina and non-Q-wave myocardial infarction (NSTEMI) (Systematic Review)

Common questions about Conpac (FAQ)

---

Q: Is there a black box warning?

The term Boxed Warning is used by the FDA for the most serious safety information required on certain product labels. According to the official FDA Prescribing Information for Conpac, there is no Boxed Warning listed in the dedicated section of the label.

---

Q: What strengths are available?

Conpac is supplied as a combination co-pack containing two different medicines. The official dosage forms include Avutometinib capsules, available in 0.8 mg strength, and Defactinib tablets, which are available in 200 mg strength.

---

Q: Does this medicine cause weight gain?

According to the official product information, weight loss (weight decreased) was reported as a very common adverse reaction in clinical trials, meaning it was observed in 10% or more of patients. Weight gain is not listed among the common or very common side effects reported in these regulatory documents.

---

Q: Can I drink alcohol while taking this medicine?

Official product information indicates that Conpac has an interaction classified as an alcohol/food interaction. While regulatory documents do not provide specific instructions for consumption, the presence of this general caution indicates the topic is an area of required discussion with a qualified health professional.

---

Q: Can I drive while taking this medicine?

Official product information reports that common side effects observed in clinical trials include dizziness and visual impairment. Because these effects can temporarily impact alertness and coordination, official guidance notes that these effects are a factor for consideration when engaging in activities that require concentration, such as driving or operating heavy machinery.

---

Q: Does this medicine affect my birth control pills?

Official regulatory documents stipulate that Conpac carries a risk of Embryo-Fetal Toxicity, meaning it may cause harm to a developing fetus. Therefore, females of reproductive potential must verify non-pregnant status and utilize effective contraception throughout treatment and for a specified duration following the last dose.

---

Official Storage and Disposal Requirements

Conpac (avutometinib capsules and defactinib tablets) must be stored strictly according to the official labeling requirements to maintain product stability and safety.

Storage Scope	Requirement from Official Labeling
Temperature	Store refrigerated between 2 C to 8 C (36 F to 46 F). Do not freeze.
Container & Handling	Keep in the original, tightly closed bottles and carton. The desiccant in the Avutometinib bottle must not be removed. Caregivers should avoid direct contact with the pills.
Child Safety	Must be kept out of the sight and reach of children and pets. The bottles are supplied with child-resistant closures.
Disposal	Disposal of unused or expired medicine must be via a drug take-back program. If this option is unavailable, the product should be mixed with an undesirable substance, sealed, and placed in the household trash. Do not flush the medication down a toilet or pour it down a drain.

These official rules govern the product's 30-month expiration dating, which is granted only when continuous refrigerated storage is maintained.